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Lynch syndrome, also called hereditary non-polyposis colorectal
cancer (HNPCC), is an autosomal dominant cancer susceptibility syn-
drome caused by germline mutations in DNAmismatch repair (MMR)
genes,MLH1,MSH2, and less frequentlyMSH6 and PMS2. MMR muta-
tion carriers are predisposed primarily to colorectal cancer and endo-
metrial cancer, with an increased frequency of stomach, ovary,
pancreas, upper urinary tract, brain, small bowel, and skin consistent-
ly reported. This hereditary syndrome accounts for approximately
2–3% of colorectal cancers and 1–4% of endometrial cancers in the
United States (Lynch and de la Chapelle, 2003). Depending on the
MMR gene involved, women with Lynch syndrome can have up to
an 80% lifetime risk of developing colorectal cancer, and a 20–60%
risk of endometrial cancer.
Germline mutations in BRCA1 or BRCA2 (BRCA1/2) cause heredi-
tary breast ovarian cancer syndrome. Female carriers of BRCA1/2 mu-
tations have excessive risks for both breast and ovarian cancer, with
lifetime breast cancer estimates ranging from 45% to 84%, and lifetime
ovarian cancer estimates ranging from 11% to 62%, depending upon
the population studied. BRCA1/2 kindreds are also noted to have an
increased frequency of prostate cancer, and in BRCA2 kindreds, in-
creased frequencies of pancreatic cancer and melanoma are observed.
The frequency of BRCA1 or BRCA2mutations in the general population
is estimated to be 1 in 300 to 1 in 800, respectively (King et al., 2003).
While there are kindreds with more than one cancer susceptibility
syndrome and/or mutation reported in the literature (Thiffault et al.,
2004; Smith et al., 2008), they are not often encountered in routine clin-
ical settings. We report on a young woman who presented to our insti-
tution for prophylactic bilateral salpingo-oophorectomy (BSO) due to
previously identiﬁed BRCA2 mutation, (i.e. 5946delT). An early endo-
metrial cancer was identiﬁed. While endometrial cancer diagnosed
under the age of 50 is not included in the Revised Bethesda Guideline,
evidence suggests that these individuals should be evaluated for Lynch
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triple heterozygosity for BRCA2,MLH1 andMSH6mutations.
Clinical history
A 41-year-old G4P4 patient presented to our institution for pro-
phylactic bilateral salpingo-oophorectomy due to a known BRCA2
mutation, which was also documented in her mother and consistent
with several cases of ovarian cancer in this lineage. She had been fol-
lowed with alternating serum CA125 and transvaginal ultrasound
every 6 months, and annual mammogram and MRI of breast were
negative. She then reported abnormal uterine bleeding. Dilation and
curettage of the endometrium revealed complex endometrial hyper-
plasia with atypia. The patient underwent hysterectomy with bilateral
salpingo-oophorectomy. Paternal family history at this timewas notable
only for an aunt with colon and stomach cancer in her 60's.
Histology and immunohistchemistry
The hysterectomy and bilateral salpingoophorectomy specimen
was received in the pathology laboratory. The uterine fundus was sec-
tioned and entirely submitted for histologic examination. The sec-
tions showed multiple residual foci of complex atypical hyperplasia
and several scattered foci of well to moderately differentiated endo-
metrioid adenocarcinoma (FIGO II) with superﬁcial myometrial inva-
sion (Fig. 1A–B). The neoplastic cells invaded the myometrium to a
depth of 0.3 cm where the myometrium measured 2.0 cm in thick-
ness. Scattered lymphocytic inﬁltration was identiﬁed at the margins
of the tumor (40 tumor-inﬁltrating lymphocytes/10 high power
ﬁelds) (Fig. 1C). Immunohistochemical stains for p53 were performed
on several sections and demonstrated no evidence of papillary serous
carcinoma component (Fig. 1D).
Microsatellite analysis by PCR
Normal and tumor tissues were microdissected and DNA was
extracted separately from the different areas. PCR ampliﬁcation was
performed for the microsatellite loci including BAT25, BAT26,
D2S123, D5S346, and D17S250, as recommended by the revised
guidelines issued by the International Collaborative Group on
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Fig. 1. Histology of the endometrial cancer. A. Moderately differentiated endometrioid adenocarcinoma. B. Superﬁcial myometrial invasion of the tumor. C. Scattered lymphocytic
inﬁltration into the tumor ( at least 40 lymphocyte/10 high power ﬁeld). D. Immunohistochemical staining of p53 shows negative staining. (A–C. Hematoxylin–eosin stain, 100×. D.
Immunohistochemical stain of p53, 100×).
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microsatellite instability (MSI) in foci of BAT25, BAT26, and D5S346,
suspicious for MSI in focus of D2S123, and microsatellite stable in
D17S250 (Fig. 2). MSI in at least 2 out of 5 microsatellite loci is classi-
ﬁed as MSI-high (MSI-H). So a DNAmismatch repair deﬁciency is pre-
sent in this endometrioid carcinoma.
Immunohistochemistry (IHC) of mismatch repair (MMR) proteins
IHC of MMR proteins including MLH1, PMS2, MSH2, and MSH6 is
based on determining complete loss or signiﬁcantly attenuated nuclear
staining for these proteins in the tumor compared with intact stainingA
C
Fig. 2.Microsatellite instability by PCR. A. BAT25 in normal control. B. BAT25 with microsate
the patient.in adjacent normal tissue and inﬂammatory cells. This patient's tumor
showed loss of MLH1 and PMS2 immunostaining and weak expression
of MSH6 (Fig. 3). This patient must have a primary expression loss or
abnormality of the hMLH1 protein, which causes advanced degradation
of the normally expressed hPMS2 protein due to inability to form the
hMutLa heterodimer. This proﬁle is consistent with microsatellite
instability.
Sequencing of MMR genes
The patient was referred for genetic counseling and germline
Lynch syndrome testing based on her early onset endometrial cancerB
D
llite instability in the patient. C. BAT 26 in normal control. D. BAT26 microinstability in
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Fig. 3. Immunohistochemistry staining of mismatch repair proteins. A. Loss of MLH1 expression (200×). B. Loss of PMS2 expression (200×). C. Expression of MSH2 (200×). D. Weak
expression of MSH6 (200×).
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the time of genetic counseling, nor was precise information regarding
a Lynch syndrome workup in her paternal lineage. Therefore, concur-
rent analysis ofMLH1,MSH2 andMSH6was requested on a peripheral
blood sample. These studies revealed two deleterious MMR muta-
tions: germline MLH1 mutation R226L (677 G>T), consisting of a nu-
cleotide substitution immediately adjacent to intron 8; and germline
MSH6 mutation 3959del4, resulting in premature truncation of the
MSH6 protein at amino acid position 1325. While the patient's
MLH1mutation carrier status was consistent with her tumor IHC pro-
ﬁle and her aunt and cousin have only MLH1mutation, theMSH6mu-
tation was not expected. Because of the unusual nature of this case, a
second sample was obtained for conﬁrmatory germline studies,
which again conﬁrmed the presence of the MLH1 and MSH6
mutations.
Genetic counseling implications
The patient was followed up with colonoscopy, esophagogastro-
duodenoscopy and endoscopic retrograde cholangiopancreatogram
(ERCP) to rule out any precancerous change or cancer in the gastroin-
testinal and hepatobilliary systems. No changes were seen in the
esophagus, stomach, duodenum, pancreas, and small or large bowels.
Discussion
We reported a case of endometrial cancer in a young patient with
both HNPCC and BRCA2 mutations. The tumor has the histologic fea-
tures of endometrioid adenocarcinoma with tumor-inﬁltrating lym-
phocytes. The tumor inﬁltration lymphocytes are commonly seen in
MSI related cancer, including endometrial cancer. The tumor also
has positive MSI by PCR, loss of MLH1 and PMS2 by IHC, and muta-
tions of MSH1 and MSH6 gene by genomic sequencing.
While it is clear that the patient inherited her BRCA2 mutation
from her mother, and it is presumed that she inherited herMLH1mu-
tation from her father, the origin of her MSH6 mutation is not clear
based on pedigree analysis alone. MSH6 carriers are at increased risk
for gynecologic cancers and males have a lower colon cancer risk
than MLH1 or MSH2 carriers. For this reason, the MSH6 mutation
could be “hiding” on either side of the family; the possibility of a de
novo mutation also remains. Attempts to test parents have thus far
been unsuccessful.In the previous reported single kindred with both MSH2 and BRCA2
mutation, there are only two caseswith double heterozygotes. The dou-
ble heterozygotes in this kindred do not appear to have an earlier age of
onset than carriers of a single mutation, and the cancers appear to have
independent genetic aetiologies (Thiffault et al., 2004). Our patient has
both BRCA2 and MMR (MSH1 and MSH6) mutations. BRCA2 mutation
has an increased risk of serious papillary carcinoma involving ovaries
and fallopian tubes. The endometrial carcinomas in BRCA2 positive pa-
tients are more likely to be serous type. The endometrioid cancer in our
patient is more correlated with MLH1 and MSH6 mutation.
A primary expression loss or abnormality of the MLH1 protein will
cause advanced degradation of the normally expressed PMS2 protein
due to inability to form the hMutLa heterodimer (Karamurzin and
Rutgers, 2009). Cases with primary mutation of MSH2 may show
weak or negative immunohistochemical staining for both MSH2 and
MSH6 due to the same mechanism of degradation of the MSH6 pro-
tein due to lack of stabilization of the hMutSa heterodimer. The pri-
mary mutation of PMS2 will result in isolated loss of PMS2.
Similarly, the mutation of MSH6 will result in isolated loss of MSH6
(Karamurzin and Rutgers, 2009). Our patient had MLH1 mutation
and showed loss of expression of MLH1 and PMS2.
Although the patient had MSH6 gene mutation, the IHC show weak
expression of MSH6. A prior study investigating mutations and IHC
ﬁndings in 25 index patients and 8 relativeswithMSH6 variantwas sig-
niﬁcant for deletion of 5 different truncating mutations and 10 variants
of missense mutation in MSH6. Twelve of 18 tumors of truncating-
mutation carriers and 3 of 17 tumors of missense-mutation carriers
showed loss of MSH6 staining. Most missense mutation carriers still
show MSH6 expression by immunostaining (Berends et al., 2002). In
our case there was a truncating mutation at the end of the MSH6 pro-
tein, likely sufﬁcient to produce protein that could be detected by IHC
but was functionally aberrant. MSH6 mutation is usually inherited
from parents rather than acquired after birth. The patient's aunt and
cousin have only MLH1 mutation but no MSH6 mutation. So the
mother's status of MSH6 should be further investigated.
Our case also raises questions about the ideal molecular workup
for Lynch syndrome. Had we used an IHC guided approach, the
MSH6 mutation would have been missed. Had we used the common-
ly accepted “test for MLH1 andMSH2, with reﬂex MSH6 testing only if
the ﬁrst two are negative” algorithm, the MSH6 mutation would have
been missed. While double heterozygosity for Lynch syndrome might
not affect the patient's cancer risk assessment and surveillance, it will
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50 risk for hereditary breast ovarian cancer syndrome, each child has
a 75% chance of having at least one Lynch syndrome causing mutation.
We are the ﬁrst group to report concurrent MLH1 and MSH6 mu-
tation in Lynch syndrome. However, more cases may have been
missed by following current IHC guided approach or by MSH6 reﬂex
test algorithm. MSH6 staining could still be positive with MSH6 mis-
sense mutation or terminal truncating mutation. We would recom-
mend including MSH6 IHC in the initial screening test. When IHC
results are equivocal, sequencing of MMR genes is the gold standard.
Different groups of investigators have reported that the risk of en-
dometrial cancer is signiﬁcantly lower in families with MLH1 muta-
tion, but much higher in families with only MSH6 mutations, which
indicates that the tumorigenic pathways between endometrial and
colorectal cancers may be different. The TGFBR2(A)10 intragenic re-
peat showed instability in carcinomas of the rectum and urothelium,
although it was not altered among the endometrial and ovarian tu-
mors (Zaanan et al., 2011; Yamamoto et al., 2001). MSH6 inactivation
may select for a different tumor suppressor gene.
Defects in MMR result in the accumulation of somatic mutations in
genes containing microsatellite repeated sequences. Accumulation of
such mutations is considered as the major molecular mechanism driv-
ing MMR-deﬁcient cells oncogenic transformation. Several target
genes involved in key cellular functions such as DNA damage signalling
and repair, apoptosis, signal transduction and transcription regulation
are suspected to play a critical role in tumour initiation and/ or progres-
sion (Zaanan et al., 2011). Acquired BRCA2 gene mutation has been
reported in a patient with widespread MSI (Yamamoto et al., 2001).
Patients with BRCA 1 or BRCA 2mutation usually undergo prophy-
lactic mastectomy and oophorectomy to prevent cancer. A recent
study in 2011 investigates the cost-effectiveness of prophylactic
surgery versus surveillance in women with Lynch syndrome andconcluded that risk-reducing surgery is the least expensive option
(Yang et al., 2011). More studies are suggesting that patients with
germline mutations in DNA mismatch repair genes should receive
counseling about colectomy, and if women, prophylactic hysterectomy
and bilateral oophorectomy (Yang et al., 2011).
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